Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).
Stroes CI, Schokker S, Khurshed M, van der Woude SO, Mathôt RA, Slingerland M, de Vos-Geelen J, Zucchetti M, Matteo C, van Dijk E, Ylstra B, Thijssen V, Derks S, Godefa T, Dijksterhuis W, Breimer GE, van Delden OM, Verhoeven RH, Meijer SL, Bijlsma MF, van Laarhoven HW. Stroes CI, et al. Among authors: schokker s. Ther Adv Med Oncol. 2022 Jun 28;14:17588359221109196. doi: 10.1177/17588359221109196. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35782751 Free PMC article.
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).
Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM. Schokker S, et al. Cancers (Basel). 2019 Jun 14;11(6):827. doi: 10.3390/cancers11060827. Cancers (Basel). 2019. PMID: 31207904 Free PMC article.
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.
Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. Stroes CI, et al. Among authors: schokker s. Cancers (Basel). 2021 Feb 17;13(4):839. doi: 10.3390/cancers13040839. Cancers (Basel). 2021. PMID: 33671266 Free PMC article.
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, Bennink RJ, Mathôt RAA, Krishnadath KK, Punt CJA, Verhoeven RHA, van Oijen MGH, Creemers GJ, Nieuwenhuijzen GAP, van der Sangen MJC, Beerepoot LV, Heisterkamp J, Los M, Slingerland M, Cats A, Hospers GAP, Bijlsma MF, van Berge Henegouwen MI, Meijer SL, van Laarhoven HWM. Stroes CI, et al. Among authors: schokker s. J Clin Oncol. 2020 Feb 10;38(5):462-471. doi: 10.1200/JCO.19.01814. Epub 2019 Dec 6. J Clin Oncol. 2020. PMID: 31809243 Free PMC article. Clinical Trial.
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. van den Ende T, et al. Among authors: schokker s. Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504550 Clinical Trial.
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM, Creemers A, van den Ende T, Schokker S, Krausz S, Reinten RJ, Dijk F, van Noesel CJM, Halfwerk H, Meijer SL, Mearadji B, Derks S, Bijlsma MF, van Laarhoven HWM. van Velzen MJM, et al. Among authors: schokker s. Gastric Cancer. 2022 Sep;25(5):906-915. doi: 10.1007/s10120-022-01313-w. Epub 2022 Jun 28. Gastric Cancer. 2022. PMID: 35763187 Free PMC article.
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, van Delden OM, Halfwerk H, van Hooft JE, van Lienden KP, Marchegiani G, Meijer SL, van Noesel CJ, Reinten RJ, Roos E, Schokker S, Verheij J, van de Vijver MJ, Waasdorp C, Wilmink JW, Ylstra B, Besselink MG, Bijlsma MF, Dijk F, van Laarhoven HW. Strijker M, et al. Among authors: schokker s. Int J Cancer. 2020 Mar 1;146(5):1445-1456. doi: 10.1002/ijc.32586. Epub 2019 Aug 13. Int J Cancer. 2020. PMID: 31340061 Free PMC article.
25 results